|
2023
|
Invention
|
Novel fusion protein specific for cd137 and cd228. The disclosure provides antibodies or antigen-... |
|
|
Invention
|
Process for purifying fusion proteins. The present disclosure relates to a method for purifying f... |
|
2022
|
Invention
|
Novel il-18 variants. The present disclosure relates to variants of human interleukin-18 (IL-18) ... |
|
|
P/S
|
Chemical preparations for industrial and scientific purposes; polypeptides and proteins produced ... |
|
|
P/S
|
Chemical preparations for industrial and scientific
purposes; polypeptides and proteins produced... |
|
|
Invention
|
Novel fusion protein specific for ox40 and pd-l1. The disclosure provides fusion proteins specifi... |
|
|
Invention
|
Engineered t cells and uses therefor.
Lipocalin muteins specific to a predetermined antigen can ... |
|
|
Invention
|
Lipocalin muteins with binding affinity for ox40. The present disclosure provides human lipocalin... |
|
|
Invention
|
Novel lipocalin muteins specific for connective tissue growth factor (ctgf).
The present disclos... |
|
|
Invention
|
Novel lipocalin muteins specific for connective tissue growth factor (ctgf). The present disclosu... |
|
|
Invention
|
Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor.... |
|
|
Invention
|
Her2/4-1bb bispecific fusion proteins for the treatment of cancer.
The disclosure provides metho... |
|
|
Invention
|
Her2/4-1bb bispecific fusion proteins for the treatment of cancer. The disclosure provides method... |
|
|
Invention
|
Proteins specific for cd137. The present disclosure provides human lipocalin muteins that bind CD... |
|
2021
|
Invention
|
Lipocalin muteins with binding affinity for lag-3. The present disclosure provides human tear lip... |
|
|
Invention
|
Biomarker methods and uses.
The disclosure provides methods for predicting a positive clinical o... |
|
|
Invention
|
Biomarker methods and uses. The disclosure provides methods for predicting a positive clinical ou... |
|
|
Invention
|
Multimeric immunomodulator targeting 4-1bb.
The disclosure provides multimeric proteins comprisi... |
|
|
Invention
|
Multimeric immunomodulator targeting 4-1bb. The disclosure provides multimeric proteins comprisin... |
|
|
Invention
|
Anti-cancer fusion polypeptide capable of binding both cd137 and glypican-3 (gpc3). The disclosur... |
|
2020
|
Invention
|
Tear lipocalin muteins binding il-4 r alpha.
The present invention relates to novel muteins deri... |
|
|
Invention
|
Anti-cancer fusion polypeptide.
The disclosure provides a fusion polypeptide specific for both C... |
|
|
Invention
|
Specific-binding polypeptides and uses thereof. The present invention relates to novel, specific-... |
|
|
Invention
|
Inhaled administration of lipocalin muteins.
The present invention relates to inhaled administra... |
|
|
Invention
|
Inhaled administration of lipocalin muteins. The present invention relates to inhaled administrat... |
|
|
Invention
|
Novel fusion proteins specific for cd137 and gpc3.
The disclosure provides fusion proteins speci... |
|
|
Invention
|
Novel fusion proteins specific for cd137 and gpc3. The disclosure provides fusion proteins specif... |
|
2019
|
Invention
|
Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereof.... |
|
|
Invention
|
Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hngal) which bi... |
|
|
Invention
|
Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (lag3) and meth... |
|
|
Invention
|
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses t... |
|
|
Invention
|
Novel fusion protein specific for cd137 and pd-l1.
The disclosure provides fusion proteins speci... |
|
|
Invention
|
Novel fusion protein specific for cd137 and pd-l1. The disclosure provides fusion proteins specif... |
|
|
Invention
|
Humanized anti-pd-1 antibodies and uses thereof. The disclosure provides, among other things, hum... |
|
|
Invention
|
Proteins specific for calcitonin gene-related peptide. The present disclosure provides hNGAL mute... |
|
|
Invention
|
Fusion molecules. P. aeruginosa biofilm infection. The present invention also concerns methods of... |
|
|
Invention
|
Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (gpc3).... |
|
|
Invention
|
Tear lipocalin muteins binding il-4 r alpha. The present invention relates to novel muteins deriv... |
|
2018
|
Invention
|
Novel proteins specific for pyoverdine and pyochelin.
The present disclosure provides hNGAL mute... |
|
|
Invention
|
Muteins of tear lipocalin and methods for obtaining the same.
The present invention relates to n... |
|
|
Invention
|
Methods for preventing or treating disorders by increasing bioavailability of iron and related ph... |
|
|
Invention
|
Novel fusion polypeptides specific for lag-3 and pd-1. The disclosure provides for fusion polypep... |
|
2016
|
Invention
|
Novel fusion polypeptide specific for lag-3 and pd-1.
The disclosure provides a fusion polypepti... |
|
|
Invention
|
Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (lag-3) and metho... |
|
|
Invention
|
Anti-cancer fusion polypeptide. The disclosure provides a fusion polypeptide specific for both CD... |
|
2008
|
P/S
|
Chemicals used in industry and science, namely, conjugates of organic and inorganic chemicals wit... |
